1-(3-溴丙氧基)-2-氯-4-甲氧基苯 | 118109-69-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3-溴丙氧基)-2-氯-4-甲氧基苯
• 英文名称: 1-(3-Bromopropoxy)-2-chloro-4-methoxybenzene
• CAS: 118109-69-6
• 化学式: C₁₀H₁₂BrClO₂
• 分子量: 279.561
• InChiKey: QKMWGRCVHIFDLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-溴丙氧基)-2-氯-4-甲氧基苯 在 sodium hydroxide 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 12.0h， 生成 (R)-7-[3-(2-Chloro-4-methoxy-phenoxy)-propoxy]-2-methyl-chroman-2-carboxylic acid
  参考文献：
  名称：

  (2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

  摘要：

  A SAR study was conducted on chromane-2-carboxylic acid toward selective PPAR alpha agonisim. As a result, highly potent, and selective PPAR alpha agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.028
• 作为产物：
  描述：

  2-氯-4-甲氧基苯酚 、 1,3-二溴丙烷 在 caesium carbonate 作用下， 生成 1-(3-溴丙氧基)-2-氯-4-甲氧基苯
  参考文献：
  名称：

  (2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

  摘要：

  A SAR study was conducted on chromane-2-carboxylic acid toward selective PPAR alpha agonisim. As a result, highly potent, and selective PPAR alpha agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.028

文献信息

• Synthesis of some phosphonates with antiherpetic activity
  作者：G. D. Diana、E. S. Zalay、U. J. Salvador、F. Pancic、B. Steinberg

  DOI：10.1021/jm00371a024

  日期：1984.5

  Several keto phosphonates, phosphonoacetates , and dialkyl phosphonates containing (aryloxy)aryl groups were synthesized and evaluated for antiherpteic activity. Two of the most active compounds, 12 and 16, were evaluated topically in the mouse vaginal model against herpes simplex virus (HSV) type 2. Compound 16 exhibited an increased survival rate, as well as increased survival time. Evaluation of

  合成了几种含（芳氧基）芳基的酮基膦酸酯，膦酸酯，和二烷基膦酸酯，并评估了其抗疱疹活性。在小鼠阴道模型中针对2型单纯疱疹病毒（HSV）局部评估了活性最高的两种化合物12和16。化合物16的存活率提高了，存活时间也增加了。在豚鼠皮肤试验中针对HSV-2进行的评估中有16项评估导致病毒效价以及平均囊泡评分降低。
• Pharmaceutically active compounds
  申请人：SCHERING CORPORATION

  公开号：EP0274867A2

  公开（公告）日：1988-07-20

  The disclosed invention is compounds represented by the formula and pharmaceutically acceptable acid addition, basic addition and quarternary amine salts thereof and pharmaceutically acceptable solvates thereof, wherein each Z is independently tetiary butyl, phenyl, naphthyl or adamantyl; substituted phenyl, wherein the substituents are one or more of halogen, lower alkoxy, phenoxy, nitrile. nitro, phenyslsulfonyl, loweralkylsulfonyl, oxazol-2-yl, lower alkanoyl, benzoyl, lower alkoxycarbonyl, lower alkyl, lower alkylthio, phenyl, phenylaminothiocarbonyl, or lower alkylaminothiocarbonyl; 4 or 6 membered unsubstituted or substituted heterocyclic ring containing at least one nitrogen with the remaining members of the ring being at least one carbon, and optionally sulfur or oxygen, wherein the substituents are one or more of carboxyl, hydroxymethyl, lower alkyl, loweralkylcarbonyl or aryl lower alkyl; X and Y are each independently a bond, -0-, each Q is independently a divalent substituted or unsubstituted, straigh or branched chain lower alkanediyl, lower alkanediyl-cycloalkaneidyl-lower alkanediyl, lower alkenediyl, lower alkynediyl, phenylene, dihydrofurandiyl, tetrahydrofurandiyl, tetrahydropyrandiyl, or, loweralkanediyl-tetrahydrofurandiyl-loweralkanediyl, wherein the substituents are one or more of hydroxy, epoxy, fluorine, chlorine, azide, or amino; W is a monovalent substituted or unsubstituted aryl group or a heterocyclic single or fused ring containing from 4 to 10 ring atoms, at least one hetero atom of which is a nitrogen atom and the remaining ring atoms being at least one carbon and optionally sulfur or oxygen, wherein the substituents are one or more of hydroxy, oxo amino, carbamoyl, carboxyl, nitrile, nitro, lower alkoxy carbonyl, halogen, sulfamyl, lower alkyl, lower alkylthio, lower alkoxy, hydroxyloweralkyl, lower alkoxycarbonylloweralkyl, amino loweralkyl, carboxyloweralkyl, guanidino, thioureido, lower alkylsulfonylamino, aminocarbonylloweralkyl, allyloxycarbonylmethyl or carbamoyloxyloweralkyl; with the proviso that W cannot be substituted or unsubstituted isoxazolyl, and W' is divalent W. The compounds have antiviral activity, antiinflammatory activity and are PAF inhibitors.

  本发明公开了由式表示的化合物 及其药学上可接受的酸加成盐、碱加成盐和季胺盐以及药学上可接受的溶液，其中 每个 Z 独立地为叔丁基、苯基、萘基或金刚烷基；取代的苯基，其中取代基为卤素、低级烷氧基、苯氧基、腈中的一个或多个。硝基、苯磺酰基、低级烷基磺酰基、噁唑-2-基、低级烷酰基、苯甲酰基、低级烷氧羰基、低级烷基、低级烷硫基、苯基、苯基氨基硫代羰基或低级烷基氨基硫代羰基中的一种；4 或 6 个成员的未取代或取代的杂环，其中至少含有一个氮，环的其余成员至少含有一个碳，可选的还有硫或氧，其中取代基为羧基、羟甲基、低级烷基、低级烷基羰基或芳基低级烷基中的一个或多个； X 和 Y 各自独立地为键、-0-、 每个 Q 独立地为二价取代或未取代的、直链或支链低级烷二基、低级烷二基-环烷亚基-低级烷二基、低级烯二基、低级炔二基、亚苯基、二氢呋喃二基、二氢吡喃二基、二氢吡喃三基、二氢吡喃四基、二氢吡喃五基、二氢吡喃六基、二氢吡喃七基、二氢吡喃八基、二氢呋喃二基、四氢呋喃二基、四氢吡喃二基，或低级烷二基-四氢呋喃二基-低级烷二基，其中取代基为羟基、环氧基、氟基、氯基、叠氮基或氨基中的一种或多种；W 是一价取代或未取代的芳基，或含有 4 至 10 个环原子的杂环，其中至少一个杂原子为氮原子，其余环原子至少为一个碳原子，可选为硫原子或氧原子，其中取代基为羟基、氧氨基、氨基甲酰基、羧基中的一个或多个、氨基甲酰基、羧基、腈基、硝基、低级烷氧基羰基、卤素、氨基磺酰基、低级烷基、低级烷硫基、低级烷氧基、羟基低级烷基、低级烷氧基羰基低级烷基、氨基低级烷基、羧基低级烷基、胍基、硫脲基、低级烷基磺酰基氨基、氨基羰基低级烷基、烯丙基氧羰基甲基或氨基甲酰氧羰基低级烷基中的一种或多种；但 W 不能是取代或未取代的异噁唑基，且 W' 为二价 W。 这些化合物具有抗病毒活性和抗炎活性，并且是 PAF 抑制剂。
• US4171376A
  申请人：——

  公开号：US4171376A

  公开（公告）日：1979-10-16
• US4851423A
  申请人：——

  公开号：US4851423A

  公开（公告）日：1989-07-25
• US5272167A
  申请人：——

  公开号：US5272167A

  公开（公告）日：1993-12-21